Ann: ResApp Provides SMARTCOUGH-C-2 Study Update, page-18

Eyeman The 1% fail rate is very significant for many reasons including its importance to the FDA in its approval process and in relation to the commercialisation of the product. Neither the FDA or the commercial wider market would have been interested in the ResApp product had it had a 20-30% fail rate. Meaning that the App could not have been used by that percentage of patients at the very start. IMO A very big deal.